(Q77896411)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9915657%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

review article

1 reference

title

State-of-the-art update and review: clinical trials of lipid-lowering agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9915657%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

author name string

P O Kwiterovich

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9915657%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

publication date

1 December 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9915657%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Cardiology

9 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9915657%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

volume

82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9915657%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

issue

12A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9915657%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

page(s)

3U-17U; discussion 39U-41U

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9915657%20AND%20SRC:MED&resulttype=core&format=json

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

9 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

The Oslo Study: diet and antismoking advice. Additional results from a 5-year primary preventive trial in middle-aged men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Colestipol hydrochloride in hypercholesterolemic patients—Effect on serum cholesterol and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Reductase inhibitor monotherapy and stroke prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Lipid-lowering interventions in angiographic trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Are we mortgaging the medical profession?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Molecular bases of the acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Coronary risk factors and plaque morphology in men with coronary disease who died suddenly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

The antiatherogenic role of high-density lipoprotein cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

The association of low levels of HDL cholesterol and arteriographically defined coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Epidemiology of triglycerides: a view from Framingham

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

Lipids and risk of coronary heart disease. The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900957-6

10.1016/S0002-9149(98)00957-6

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9915657%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1 reference